Real‐World Alcohol Use Disorder Outcomes in Patients With Concurrent Metabolic Dysfunction: GLP ‐1 Receptor Agonists Versus FDA ‐Approved AUD Medications
Outcomes bei Alkoholgebrauchsstörung mit metabolischer Dysfunktion: GLP-1-Rezeptoragonisten versus von der FDA zugelassene AUD-Medikamente
Alimentary Pharmacology & Therapeutics · 2026-06 · 63 (11) · 1507-1516
DOI: 10.1111/apt.70596 ↗Auf einen Blick
Bei Patient:innen mit AUD und metabolischer Dysfunktion war GLP-1RA mit weniger 1-Jahres-Rückfällen und besseren metabolischen Werten verbunden als FDA-zugelassene AUD-Medikamente.
Fragestellung
Wie schneiden GLP-1-Rezeptoragonisten im Vergleich zu FDA-zugelassenen AUD-Medikamenten bei Patient:innen mit AUD und metabolischer Dysfunktion ab?
Methode
Retrospektive Kohortenstudie bei Stanford Health Care (2017–2025); Propensity-Score-Matching; Vergleich von ≥ 6 Monaten GLP-1RA (Semaglutid oder Tirzepatid) mit Naltrexon, Acamprosat oder Disulfiram.
Ergebnisse
1946 Patient:innen. GLP-1RA war mit niedrigerem 1-Jahres-AUD-Rückfall verbunden: IRR 0,55 (95 %-KI 0,42–0,73; p < 0,01). BMI sank stärker (−1,3 vs. −0,3; p = 0,004) und HbA1c verbesserte sich (−1,0 vs. +0,1; p = 0,02).
Schlussfolgerung der Autor:innen
GLP-1RAs sind nach Ansicht der Autor:innen eine vielversprechende Option bei gleichzeitigem MetD und AUD und verbesserten Rückfall- und Stoffwechselergebnisse im Vergleich zu derzeit FDA-zugelassenen AUD-Therapien.
Kernaussagen
- 1-Jahres-AUD-Rückfall: IRR 0,55 (95 %-KI 0,42–0,73)
- BMI und HbA1c verbesserten sich unter GLP-1RA stärker
- Kein signifikanter Unterschied bei dekompensierter Zirrhose; Mortalität ähnlich
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
At a glance
Vergleichsstudie in Alimentary Pharmacology & Therapeutics, published online on 2026-03-11. Written by Amir Gougol and 6 co-authors. Institution: Department of Gastroenterology and Hepatology, Stanford University, Palo Alto, CA, USA. Major MEDLINE topics: Glucagon-Like Peptide-1 Receptor Agonists, Alcoholism, Alcohol Deterrents, Metabolic Diseases. Cited 7 times so far (Crossref); 45 references.
Topics: Sucht und Abhängigkeit
Abstract (original language)
Background
Metabolic dysfunction (MetD) and alcohol use disorder (AUD) frequently coexist as synergistic risk factors for steatotic liver disease. Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are established therapies for MetD, including type 2 diabetes mellitus (T2DM) and obesity. Recent studies suggested potential beneficial effects of GLP‐1RA to decrease addictive behaviours in AUD. We evaluated the outcomes of GLP‐1RA therapy compared with FDA‐approved pharmacotherapies for AUD, including naltrexone, acamprosate, and disulfiram, in patients with dual risk factors of MetD and AUD.
Methods
We conducted a retrospective cohort study of patients at Stanford Health Care (2017–2025). Eligible patients had a concurrent diagnosis of alcohol‐related complications meeting criteria for AUD and MetD, including obesity (BMI > 25) and/or a history of T2DM with HbA1c > 5.7. Those with advanced liver disease within 1 year of diagnosis were excluded. Exposure groups included ≥ 6 months of GLP‐1RA therapy (semaglutide or tirzepatide) in comparison with FDA‐approved pharmacotherapies for AUD. Propensity score matching was employed to reduce the effects of confounding factors.
Results
In total, 1946 patients were diagnosed concurrently with AUD and MetD. Of them, 274 patients were exposed to GLP‐1RA, 1272 to naltrexone, 232 to acamprosate, and 168 to disulfiram. Patients were followed for an average of 1341 days. Patients exposed to GLP‐1RA had higher BMI (35.5 vs. 30.1) and more T2DM (66% vs. 14%). GLP‐1RA therapy was associated with lower 1‐year AUD relapse [IRR 0.55, 95% CI 0.42–0.73; p < 0.01], greater BMI reduction (−1.3 vs. –0.3; p = 0.004), and HbA1c improvement (−1.0 vs. +0.1; p = 0.02). The incidence of decompensated cirrhosis trended lower but was not statistically significant [HR 0.52, p = 0.09]. Mortality was similar.
Conclusions
GLP‐1RAs are a promising option for patients with concurrent MetD and AUD, improving relapse rates and metabolic outcomes compared with currently FDA‐approved pharmacotherapies for AUD. Trends toward better liver outcomes support further prospective evaluation.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Gastroenterology and Hepatology, Stanford University, Palo Alto, CA, USA.
- Atropos Health Inc, Indianapolis, IN, USA.
- National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism, Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and,…
- University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
ORCID profiles: Amir Gougol, Mehdi Farokhnia
Cite
APA
Gougol, A., Kwo, P., Pike, W., Farokhnia, M., Hui, G., Gombar, S., & Mirminachi, B. (2026). Real‐World Alcohol Use Disorder Outcomes in Patients With Concurrent Metabolic Dysfunction: GLP ‐1 Receptor Agonists Versus FDA ‐Approved AUD Medications. Alimentary Pharmacology & Therapeutics, 63(11), 1507-1516. https://doi.org/10.1111/apt.70596
Vancouver
Gougol A, Kwo P, Pike W, Farokhnia M, Hui G, Gombar S, et al. Real‐World Alcohol Use Disorder Outcomes in Patients With Concurrent Metabolic Dysfunction: GLP ‐1 Receptor Agonists Versus FDA ‐Approved AUD Medications. Alimentary Pharmacology & Therapeutics. 2026;63(11):1507-1516. doi:10.1111/apt.70596
BibTeX
@article{Gougol2026,
author = {Gougol, Amir and Kwo, Paul and Pike, William and Farokhnia, Mehdi and Hui, Gavin and Gombar, Saurabh and Mirminachi, Babak},
title = {Real‐World Alcohol Use Disorder Outcomes in Patients With Concurrent Metabolic Dysfunction: GLP ‐1 Receptor Agonists Versus FDA ‐Approved AUD Medications},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
volume = {63},
number = {11},
pages = {1507--1516},
doi = {10.1111/apt.70596}
}
EUVIMED